WO2012040754A3 - Nouveaux dérivés de thiazolamine comme accélérateurs de différenciation - Google Patents

Nouveaux dérivés de thiazolamine comme accélérateurs de différenciation Download PDF

Info

Publication number
WO2012040754A3
WO2012040754A3 PCT/AT2011/000393 AT2011000393W WO2012040754A3 WO 2012040754 A3 WO2012040754 A3 WO 2012040754A3 AT 2011000393 W AT2011000393 W AT 2011000393W WO 2012040754 A3 WO2012040754 A3 WO 2012040754A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazolamine
case
derivates
novel
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2011/000393
Other languages
German (de)
English (en)
Other versions
WO2012040754A2 (fr
Inventor
Marko D. Mihovilovic
Michael SCHNÜRCH
Birgit Waldner
Karlheinz Hilber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Wien
Original Assignee
Technische Universitaet Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Wien filed Critical Technische Universitaet Wien
Publication of WO2012040754A2 publication Critical patent/WO2012040754A2/fr
Publication of WO2012040754A3 publication Critical patent/WO2012040754A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un dérivé de thiazolamine pour accélérer la différenciation de cellules, caractérisée en ce que l'on utilise un dérivé de 2-thiazolamine de la formule générale suivante : dans laquelle R1 à R3 sont choisis indépendamment les uns des autres parmi l'hydrogène, le benzyle, un aryle et un hétéroaryle ou bien sont absents, au maximum un des restes R1 à R3 étant un hydrogène, et R4 est choisi parmi le benzyle, un aryle et un hétéroaryle, les restes R1 à R4 pouvant être substitués indépendamment les uns des autres par un ou plusieurs substituants choisis parmi un halogène (F, Cl, Br, I) ou un groupe hydroxy, alkyle en C1-3, alcoxy en C1-3, carboxy, alkylcarbonyle en C1-3, alcoxycarbonyle en C1-3, nitro, amino, mono- et dialkylamino en C1-3 ainsi que cyano, dans lequel les groupes alkyle peuvent être halogénés ; - - - (aa) représente respectivement une liaison simple ou une liaison double ; n = 0 à 2 et, lorsque n = 1, le reste R4 peut être rattaché dans la position 4 ou dans la position 5 du noyau cyclique thiazole et, lorsque n = 2, les restes R4 sont rattachés dans les positions 4 et 5 du noyau cyclique thiazole.
PCT/AT2011/000393 2010-09-27 2011-09-26 Nouveaux dérivés de thiazolamine comme accélérateurs de différenciation Ceased WO2012040754A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1614/2010 2010-09-27
AT16142010A AT510456B1 (de) 2010-09-27 2010-09-27 Thiazolamin-derivate als zelldifferenzierungsbeschleuniger

Publications (2)

Publication Number Publication Date
WO2012040754A2 WO2012040754A2 (fr) 2012-04-05
WO2012040754A3 true WO2012040754A3 (fr) 2012-06-21

Family

ID=45841132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2011/000393 Ceased WO2012040754A2 (fr) 2010-09-27 2011-09-26 Nouveaux dérivés de thiazolamine comme accélérateurs de différenciation

Country Status (2)

Country Link
AT (1) AT510456B1 (fr)
WO (1) WO2012040754A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051424A1 (fr) 2018-09-07 2020-03-12 Pic Therapeutics Inhibiteurs d'eif4e et leurs utilisations
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
CA3229560A1 (fr) 2021-08-25 2023-03-02 Christopher L. Vandeusen Inhibiteurs d'eif4e et leurs utilisations
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112693A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
WO2010127878A2 (fr) * 2009-05-08 2010-11-11 Sygnis Bioscience Gmbh & Co. Kg Utilisation du thiabendazole et de ses dérivés dans le traitement des affections neurologiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO2005047524A2 (fr) * 2003-11-10 2005-05-26 The Scripps Research Institute Compositions et procedes pour induire la differenciation cellulaire
US8105581B2 (en) * 2005-12-01 2012-01-31 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112693A1 (en) * 2008-10-31 2010-05-06 Alireza Rezania Differentiation of Human Embryonic Stem Cells
WO2010127878A2 (fr) * 2009-05-08 2010-11-11 Sygnis Bioscience Gmbh & Co. Kg Utilisation du thiabendazole et de ses dérivés dans le traitement des affections neurologiques

Also Published As

Publication number Publication date
AT510456B1 (de) 2012-11-15
AT510456A1 (de) 2012-04-15
WO2012040754A2 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
EP4295841A3 (fr) Composés de fluorure de soufre (vi) et leurs utilisation dans les réactions click
WO2012080284A3 (fr) Composés hétérocycliques azotés 6,6-condensés substitués et leurs utilisations
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
MY160490A (en) Arylethynyl derivatives
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
WO2011101069A3 (fr) Hétarylaminonaphtyridines
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
WO2014100764A3 (fr) Procédés d'inhibition de prmt5
WO2009122034A8 (fr) Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation
SV2010003502A (es) Fungicidas novedosos
WO2011088027A8 (fr) Composés et procédés
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MX2011007998A (es) Nuevos herbicidas.
WO2012101011A3 (fr) Nouveaux dérivés d'arylbenzocycloalkylamides
BR112014010644A2 (pt) novos derivados de aril-quinolina
MX2015007883A (es) Compuestos para protección de células.
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
MY161132A (en) Novel herbicides
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
TN2015000261A1 (fr) Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa
MX2011007932A (es) Herbicidas nuevos.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11826129

Country of ref document: EP

Kind code of ref document: A2